Deinove

Investment summary

Deinove is running an Phase II trial with its novel quinolonyl-oxazolidinone class antibiotic DNV3837 for moderate to severe Clostridium difficile infections. This is an open-label study being conducted in two parts across 15 centres in the US. An interim analysis by data and safety monitoring board is expected mid-2021 prior to commencement of the second part of the trial which will randomise 30 patients and assess efficacy endpoints. In March, Deinove reported it had been awarded a €500–800k grant by the French government to develop its Boost-ID project; it will use the proceeds to implement a high-throughput antimicrobial screening platform, anticipated to be operational by end-2021. In January, Deinove issued the 4th and 5th tranches of its convertible note programme with an aggregate value of €4.5m.